Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. on June 3, 2021, covering the month of June 2021. The registrant is a foreign private issuer based in Kfar Saba, Israel, filing under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
The primary material change disclosed is the termination of Eyal Leibovitz as Chief Financial Officer. Mr. Leibovitz will continue to serve in his primary CFO capacity through August 31, 2021, to facilitate the anticipated closing of a strategic merger with privately-held Quoin Pharmaceuticals, Inc.
Guidance, Outlook, and Risks
Management commentary indicates an expectation that the strategic merger with Quoin Pharmaceuticals, Inc. will close by August 31, 2021. No specific financial guidance, risk factors, or contingencies were detailed in this specific filing text.
Key Facts for Investor Verification
- Confirmation of the strategic merger timeline with Quoin Pharmaceuticals, Inc.
- Identification of the successor to Eyal Leibovitz as CFO after August 31, 2021.
- Verification of the merger closing status and any associated financial impacts in subsequent filings.